{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:53:04Z","timestamp":1791255184945,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["112-2320-B-A49-019"],"award-info":[{"award-number":["112-2320-B-A49-019"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2628-B-009-004"],"award-info":[{"award-number":["109-2628-B-009-004"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007354","name":"Yen Tjing Ling Medical Foundation","doi-asserted-by":"publisher","award":["CI-113-2"],"award-info":[{"award-number":["CI-113-2"]}],"id":[{"id":"10.13039\/501100007354","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Enolase 2 (ENO2) is a neuron-specific glycolytic enzyme whose expression is elevated in aggressive breast cancers, yet its enzymatic and biological contributions to triple-negative breast cancer (TNBC) progression remain incompletely defined. Here, we demonstrate that ENO2 sustains cancer stem cell (CSC) properties and metastatic competence through a phosphoenolpyruvate (PEP)-dependent metabolic axis. Elevated ENO2 expression correlated with advanced tumor grade and poor clinical outcomes in TNBC cohorts, underscoring its clinical relevance. Genetic depletion of ENO2 impaired aerobic glycolysis and oxidative phosphorylation, reduced migration, invasion, and CSC frequency, and suppressed tumor growth and pulmonary metastasis in orthotopic models. Mechanistically, exogenous PEP or pyruvate restored CSC-associated traits and invasiveness in ENO2-deficient cells, supporting the functional involvement of ENO2-derived metabolites in CSC maintenance. Reconstitution with wild-type ENO2, but not a catalytically impaired mutant, restored CSC properties, invasiveness, and metastatic colonization, establishing that ENO2 catalytic activity is required for these malignant traits. Further analysis revealed that PKM2 perturbation preferentially attenuated PEP-mediated rescue while largely sparing pyruvate-mediated rescue, supporting a functional PEP-PKM2-pyruvate axis in CSC regulation. Consistently, PKM2 depletion partially blunted ENO2-mediated rescue; however, residual rescue despite PKM2 perturbation suggested additional PKM2-independent PEP-responsive mechanisms. Importantly, pharmacological inhibition of enolase with POMHEX phenocopied genetic ENO2 loss and suppressed CSC maintenance in vitro and tumor growth in vivo. Taken together, these findings identify the ENO2-driven PEP-dependent metabolic axis as a mechanistic link between metabolic reprogramming, cancer stemness, and metastasis, revealing a therapeutically actionable metabolic vulnerability in TNBC.<\/jats:p>","DOI":"10.1038\/s41419-026-09106-0","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:24:54Z","timestamp":1783772694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ENO2 sustains cancer stemness and metastatic competence through a phosphoenolpyruvate-dependent metabolic axis in triple-negative breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Cing-Hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Tsun","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke Jia","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Feng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-4902","authenticated-orcid":false,"given":"Chi-Hong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"9106_CR1","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/PL00000910","volume":"58","author":"V Pancholi","year":"2001","unstructured":"Pancholi V. Multifunctional \u03b1-enolase: its role in diseases. Cell Mol Life Sci. 2001;58:902\u201320.","journal-title":"Cell Mol Life Sci"},{"key":"9106_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/OAB.S16416","volume":"3","author":"RS Holmes","year":"2011","unstructured":"Holmes RS. Bioinformatic studies of vertebrate enolases: multifunctional genes and proteins. Open Access Bioinform. 2011;3:43\u201359.","journal-title":"Open Access Bioinform"},{"key":"9106_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.aninu.2016.02.005","volume":"2","author":"H Ji","year":"2016","unstructured":"Ji H, Wang J, Guo J, Li Y, Lian S, Guo W, et al. Progress in the biological function of alpha-enolase. Anim Nutr. 2016;2:12\u20137.","journal-title":"Anim Nutr"},{"key":"9106_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.omto.2021.12.026","volume":"24","author":"CK Huang","year":"2022","unstructured":"Huang CK, Sun Y, Lv L, Ping Y. ENO1 and cancer. Mol Ther Oncolytics. 2022;24:288\u201398.","journal-title":"Mol Ther Oncolytics"},{"key":"9106_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.21037\/atm-20-3354","volume":"8","author":"D Liu","year":"2020","unstructured":"Liu D, Mao Y, Chen C, Zhu F, Lu W, Ma H. Expression patterns and clinical significances of ENO2 in lung cancer: an analysis based on Oncomine database. Ann Transl Med. 2020;8:639.","journal-title":"Ann Transl Med"},{"key":"9106_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-020-0146-6","volume":"5","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Wu C, Yang J, Zhao Y, Jia H, Xue M, et al. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Signal Transduct Target Ther. 2020;5:53.","journal-title":"Signal Transduct Target Ther"},{"key":"9106_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3390\/cells11152363","volume":"11","author":"C Lv","year":"2022","unstructured":"Lv C, Yu H, Wang K, Chen C, Tang J, Han F, et al. ENO2 promotes colorectal cancer metastasis by interacting with the LncRNA CYTOR and activating YAP1-induced EMT. Cells. 2022;11:2363.","journal-title":"Cells"},{"key":"9106_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/or.2022.8470","volume":"49","author":"W-J Chen","year":"2023","unstructured":"Chen W-J, Yang W, Gong M, He Y, Xu D, Chen J-X, et al. ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment. Oncol Rep. 2023;49:33.","journal-title":"Oncol Rep"},{"key":"9106_CR9","doi-asserted-by":"crossref","unstructured":"Gao L, Yang F, Tang D, Xu Z, Tang Y, Yang D, et al. Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development. J Exp Clin Cancer Res. 2023;42:1.","DOI":"10.1186\/s13046-022-02574-0"},{"key":"9106_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s42255-020-00313-3","volume":"2","author":"Y-H Lin","year":"2020","unstructured":"Lin Y-H, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020;2:1413\u201326.","journal-title":"Nat Metab"},{"key":"9106_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0344-0338(88)80048-7","volume":"183","author":"J Nesland","year":"1988","unstructured":"Nesland J, Holm R, Johannessen J, Gould V. Neuroendocrine differentiation in breast lesions. Pathol Res Pract. 1988;183:214\u201321.","journal-title":"Pathol Res Pract"},{"key":"9106_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-11-41","volume":"11","author":"MA Soh","year":"2011","unstructured":"Soh MA, Garrett SH, Somji S, Dunlevy JR, Zhou XD, Sens MA, et al. Arsenic, cadmium and neuron-specific enolase (ENO2, \u03b3-enolase) expression in breast cancer. Cancer Cell Int. 2011;11:41.","journal-title":"Cancer Cell Int"},{"key":"9106_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-023-02641-0","volume":"42","author":"C De Vitis","year":"2023","unstructured":"De Vitis C, Battaglia AM, Pallocca M, Santamaria G, Mimmi MC, Sacco A, et al. ALDOC-and ENO2-driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis. J Exp Clin Cancer Res. 2023;42:69.","journal-title":"J Exp Clin Cancer Res"},{"key":"9106_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","volume":"33","author":"Y Gong","year":"2021","unstructured":"Gong Y, Ji P, Yang Y-S, Xie S, Yu T-J, Xiao Y, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33:51\u201364.e9.","journal-title":"Cell Metab"},{"key":"9106_CR15","first-page":"001","volume":"2013","author":"KA Desai","year":"2013","unstructured":"Desai KA. Triple negative breast cancer\u2013an overview. Hereditary Genet. 2013;2013:001.","journal-title":"Hereditary Genet"},{"key":"9106_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","volume":"9","author":"NM Almansour","year":"2022","unstructured":"Almansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Front Mol Biosci. 2022;9:836417.","journal-title":"Front Mol Biosci"},{"key":"9106_CR17","first-page":"101","volume":"21","author":"AK Dogra","year":"2025","unstructured":"Dogra AK, Prakash A, Gupta S, Gupta M. Prognostic significance and molecular classification of triple negative breast cancer: a systematic review. Eur J Breast Health. 2025;21:101\u201314.","journal-title":"Eur J Breast Health"},{"key":"9106_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-017-0250-9","volume":"10","author":"HH Milioli","year":"2017","unstructured":"Milioli HH, Tishchenko I, Riveros C, Berretta R, Moscato P. Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. BMC Med Genomics. 2017;10:19.","journal-title":"BMC Med Genomics"},{"key":"9106_CR19","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1158\/1541-7786.MCR-21-0098","volume":"19","author":"C-H Chao","year":"2021","unstructured":"Chao C-H, Wang C-Y, Wang C-H, Chen T-W, Hsu H-Y, Huang H-W, et al. Mutant p53 attenuates oxidative phosphorylation and facilitates cancer stemness through downregulating miR-200c\u2013PCK2 axis in basal-like breast cancer. Mol Cancer Res. 2021;19:1900\u201316.","journal-title":"Mol Cancer Res"},{"key":"9106_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940402","volume":"12","author":"C-Y Wang","year":"2022","unstructured":"Wang C-Y, Wang C-H, Mai R-T, Chen T-W, Li C-W, Chao C-H. Mutant p53-microRNA-200c-ZEB2-axis-induced CPT1C elevation contributes to metabolic reprogramming and tumor progression in basal-like breast cancers. Front Oncol. 2022;12:940402.","journal-title":"Front Oncol"},{"key":"9106_CR21","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1158\/0008-5472.CAN-05-2415","volume":"66","author":"C-H Chao","year":"2006","unstructured":"Chao C-H, Chen C-M, Cheng P-L, Shih J-W, Tsou A-P, Wu Lee Y-H. DDX3, a DEAD box RNA helicase with tumor growth\u2013suppressive property and transcriptional regulation activity of the p21waf1\/cip1 promoter, is a candidate tumor suppressor. Cancer Res. 2006;66:6579\u201388.","journal-title":"Cancer Res"},{"key":"9106_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347:70\u20138.","journal-title":"J Immunol Methods"},{"key":"9106_CR23","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22:2622.","journal-title":"Int J Mol Sci"},{"key":"9106_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baab007","volume":"2021","author":"P J\u00e9z\u00e9quel","year":"2021","unstructured":"J\u00e9z\u00e9quel P, Gouraud W, Ben Azzouz F, Gu\u00e9rin-Charbonnel C, Juin PP, Lasla H, et al. bc-GenExMiner 4.5: new mining module computes breast cancer differential gene expression analyses. Database. 2021;2021:baab007.","journal-title":"Database"},{"key":"9106_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0514-7","volume":"12","author":"S-J Park","year":"2019","unstructured":"Park S-J, Yoon B-H, Kim S-K, Kim S-Y. GENT2: an updated gene expression database for normal and tumor tissues. BMC Med Genomics. 2019;12:101.","journal-title":"BMC Med Genomics"},{"key":"9106_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00197-2","volume":"6","author":"A Marra","year":"2020","unstructured":"Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ Breast Cancer. 2020;6:54.","journal-title":"NPJ Breast Cancer"},{"key":"9106_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejmech.2017.06.064","volume":"138","author":"X Ning","year":"2017","unstructured":"Ning X, Qi H, Li R, Li Y, Jin Y, McNutt MA, et al. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell-specific M2 isoform of pyruvate kinase. Eur J Med Chem. 2017;138:343\u201352.","journal-title":"Eur J Med Chem"},{"key":"9106_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"9106_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"9106_CR30","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.3390\/cancers12102780","volume":"12","author":"A Tanabe","year":"2020","unstructured":"Tanabe A, Sahara H. The metabolic heterogeneity and flexibility of cancer stem cells. Cancers. 2020;12:2780.","journal-title":"Cancers"},{"key":"9106_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.reth.2021.01.005","volume":"17","author":"T Yasuda","year":"2021","unstructured":"Yasuda T, Ishimoto T, Baba H. Conflicting metabolic alterations in cancer stem cells and regulation by the stromal niche. Regen Ther. 2021;17:8\u201312.","journal-title":"Regen Ther"},{"key":"9106_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6990-6_1","volume":"1606","author":"SM Telloni","year":"2017","unstructured":"Telloni SM. Tumor staging and grading: a primer. Methods Mol Biol. 2017;1606:1\u201317.","journal-title":"Methods Mol Biol"},{"key":"9106_CR33","first-page":"114","volume":"38","author":"O Okcu","year":"2022","unstructured":"Okcu O, Sen B, Ozturk C, Guvendi GF, Bedir R. GLUT-1 expression in breast cancer. T\u00fcrk Patoloji Derg. 2022;38:114\u201321.","journal-title":"T\u00fcrk Patoloji Derg"},{"key":"9106_CR34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1349-7006.2002.tb01214.x","volume":"93","author":"SS Kang","year":"2002","unstructured":"Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res. 2002;93:1123\u20138.","journal-title":"Jpn J Cancer Res"},{"key":"9106_CR35","first-page":"2895","volume":"15","author":"M Younes","year":"1995","unstructured":"Younes M, Brown R, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995;15:2895\u20138.","journal-title":"Anticancer Res"},{"key":"9106_CR36","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1097\/MD.0000000000012961","volume":"97","author":"Y Deng","year":"2018","unstructured":"Deng Y, Zou J, Deng T, Liu J. Clinicopathological and prognostic significance of GLUT1 in breast cancer: a meta-analysis. Medicine. 2018;97:e12961.","journal-title":"Medicine"},{"key":"9106_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-03123-3","volume":"15","author":"HA Basheer","year":"2025","unstructured":"Basheer HA, Alkilani AZ, Bashir SA, Alhusban MA, Elsalem L, AlOmari SB, et al. Clinicopathological analysis of GLUT-1, GLS1, and GLS2 expression in breast cancer tissues from Jordanian patients. Sci Rep. 2025;15:34135.","journal-title":"Sci Rep"},{"key":"9106_CR38","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1159\/000489196","volume":"46","author":"C-c Liu","year":"2018","unstructured":"Liu C-c, Wang H, Wang W-d, Wang L, Liu W-j, Wang J-h, et al. ENO2 promotes cell proliferation, glycolysis, and glucocorticoid-resistance in acute lymphoblastic leukemia. Cell Physiol Biochem. 2018;46:1525\u201335.","journal-title":"Cell Physiol Biochem"},{"key":"9106_CR39","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1111\/cas.14929","volume":"112","author":"R Yukimoto","year":"2021","unstructured":"Yukimoto R, Nishida N, Hata T, Fujino S, Ogino T, Miyoshi N, et al. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer. Cancer Sci. 2021;112:2884\u201394.","journal-title":"Cancer Sci"},{"key":"9106_CR40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3892\/ol.2024.14576","volume":"28","author":"H Li","year":"2024","unstructured":"Li H, Wu Y, Ma Y, Liu X. Interference with ENO2 promotes ferroptosis and inhibits glycolysis in clear cell renal cell carcinoma by regulating Hippo\u2011YAP1 signaling. Oncol Lett. 2024;28:443.","journal-title":"Oncol Lett"},{"key":"9106_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cmet.2018.06.006","volume":"28","author":"M Luo","year":"2018","unstructured":"Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus JM, et al. Targeting breast cancer stem cell state equilibrium through modulation of redox signaling. Cell Metab. 2018;28:69\u201386.e6.","journal-title":"Cell Metab"},{"key":"9106_CR42","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/s42255-023-00883-y","volume":"5","author":"C Wang","year":"2023","unstructured":"Wang C, Huang M, Lin Y, Zhang Y, Pan J, Jiang C, et al. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nat Metab. 2023;5:1765\u201386.","journal-title":"Nat Metab"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09106-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09106-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09106-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:35:54Z","timestamp":1791254154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09106-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9106"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09106-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Animal protocols (IACUC No. 112051\u2009A and IACUC No. 111045) were approved by the Institutional Animal Care and Use Committee (IACUC) at National Yang Ming Chiao Tung University, Taiwan.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"864"}}